10 most popular complementary medicines may interact with cancer therapy
the ONA take:
According to new research presented at the Clinical Oncology Society of Australia's (COSA's) Annual Scientific Meeting in Melbourne, Australia, researchers at Peter MacCallum Cancer Centre in Melbourne have found that the 10 most asked about complementary medicines all may result in drug interactions with administered with chemotherapy, radiation, or prior to surgery.
For the study, researchers identified the 10 most commonly inquired about complementary medicines by providers and patients to the hospital's Medicines Information Centre. Excluding vitamins and minerals, the 10 most commonly asked about complementary medicines were: astragalus, coenzyme Q10, fish oil, ginger, green tea, lactobacillus, licorice, milk thistle, and reishi mushroom.
The researchers note that any of those found in a normal healthy diet would not likely cause adverse effects, but higher quantities consumed in complementary medicines could. These supplemental medicines have the potential to alter the effects of chemotherapy, thereby increasing the patient's risk of toxicity or decreasing the effectiveness of the chemotherapy.
Products that contain high levels of antioxidants can potentially interact with chemotherapy and radiotherapy. Patients should be aware that a natural product may not be safe and a complementary product does not necessarily complement standard cancer therapies.
10 most asked about complementary medicines all may result in drug interactions.
- Ezh2 Inhibitors May Offer Cure for Chronic Myelogenous Leukemia
- Ruxolitinib: A Targeted Treatment Option for Patients with Polycythemia Vera
- Incontinence Affects QOL for Survivors of Gynecologic Cancers
- Adding Bevacizumab to Adjuvant Capecitabine Not Effective for mCRC
- ASCO, ASTRO Issue Guideline Update for Postmastectomy RT
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- Ruxolitinib Effective as Long-term Treatment Option for Polycythemia Vera
- Definitive IMRT Associated With Shorter Feeding Tube Placement Duration in HNC
- SBRT Improves Overall and Disease-Specific Survival in Stage I NSCLC
- Patients Receiving RT in APBI Facilities Despite Eligibility for Observation
- Prolonged Imatinib Therapy Improves Likelihood of Deeper Molecular Response
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|